BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 34347284)

  • 1. FKB238: A Bevacizumab Biosimilar.
    Syed YY
    Clin Drug Investig; 2021 Sep; 41(9):825-828. PubMed ID: 34347284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Bevacizumab Biosimilar FKB238 Versus Originator Bevacizumab: Results from AVANA, a Phase III Trial in Patients with Non-Squamous Non-Small-Cell Lung Cancer (non-sq-NSCLC).
    Syrigos K; Abert I; Andric Z; Bondarenko IN; Dvorkin M; Galic K; Galiulin R; Kuchava V; Sriuranpong V; Trukhin D; Zhavrid E; Fu D; Kassalow LM; Jones S; Bashir Z;
    BioDrugs; 2021 Jul; 35(4):417-428. PubMed ID: 34264503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MYL-1402O: A Bevacizumab Biosimilar.
    Lee A
    Target Oncol; 2022 Jan; 17(1):85-88. PubMed ID: 34910269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SB8: A Bevacizumab Biosimilar.
    Syed YY
    Target Oncol; 2020 Dec; 15(6):787-790. PubMed ID: 33206282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized double-blind clinical trial comparing safety and efficacy of the biosimilar BCD-021 with reference bevacizumab.
    Stroyakovskiy DL; Fadeeva NV; Matrosova MP; Shelepen KG; Adamchuk GA; Roy B; Nagarkar R; Kalloli M; Zhuravleva D; Voevodin GD; Shustova MS; Kryukov F
    BMC Cancer; 2022 Feb; 22(1):129. PubMed ID: 35105329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase III, randomized, double-blind, multicenter study to compare the efficacy, safety, pharmacokinetics, and immunogenicity between SB8 (proposed bevacizumab biosimilar) and reference bevacizumab in patients with metastatic or recurrent nonsquamous non-small cell lung cancer.
    Reck M; Luft A; Bondarenko I; Shevnia S; Trukhin D; Kovalenko NV; Vacharadze K; Andrea F; Hontsa A; Choi J; Shin D
    Lung Cancer; 2020 Aug; 146():12-18. PubMed ID: 32502923
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics, safety, tolerability, and immunogenicity of FKB238, a new biosimilar of bevacizumab, in healthy participants.
    Boyce M; Wilkes D; Kaito H; Takanuma M; Arai Y
    Int J Clin Pharmacol Ther; 2022 Jun; 60(6):280-290. PubMed ID: 35361328
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of the proposed bevacizumab biosimilar BAT1706 compared with reference bevacizumab in patients with advanced nonsquamous non-small cell lung cancer: A randomized, double-blind, phase III study.
    Chen L; Rangel JDG; Cil T; Li X; Cicin I; Shen Y; Liu Z; Ozyilkan O; Igor B; Chen J; Oleksandr K; Chen Z; Zhang H; Fu Z; Dong Q; Song S; Yu JC; Zhang L
    Cancer Med; 2023 Nov; 12(22):20847-20863. PubMed ID: 37935428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy, Safety and Immunogenicity of MB02 (Bevacizumab Biosimilar) versus Reference Bevacizumab in Advanced Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Phase III Study (STELLA).
    Trukhin D; Poddubskaya E; Andric Z; Makharadze T; Bellala RS; Charoentum C; Yañez Ruiz EP; Fulop A; Hyder Ali IA; Syrigos K; Katgi N; Lopez Chuken YA; Rumyana I; Reyes-Igama J; Costamilan RC; Del Campo García A; Florez A; Paravisini A; Millan S;
    BioDrugs; 2021 Jul; 35(4):429-444. PubMed ID: 33914256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Candidate Bevacizumab Biosimilar CT-P16 versus European Union Reference Bevacizumab in Patients with Metastatic or Recurrent Non-Small Cell Lung Cancer: A Randomized Controlled Trial.
    Verschraegen C; Andric Z; Moiseenko F; Makharadze T; Shevnya S; Oleksiienko A; Yañez Ruiz E; Kim S; Ahn K; Park T; Park S; Ju H; Ohe Y
    BioDrugs; 2022 Nov; 36(6):749-760. PubMed ID: 36169807
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bevacizumab plus chemotherapy in nonsquamous non-small cell lung cancer patients with malignant pleural effusion uncontrolled by tube drainage or pleurodesis: A phase II study North East Japan Study group trial NEJ013B.
    Noro R; Kobayashi K; Usuki J; Yomota M; Nishitsuji M; Shimokawa T; Ando M; Hino M; Hagiwara K; Miyanaga A; Seike M; Kubota K; Gemma A;
    Thorac Cancer; 2020 Jul; 11(7):1876-1884. PubMed ID: 32421226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of the Biosimilar ABP 215 Compared with Bevacizumab in Patients with Advanced Nonsquamous Non-small Cell Lung Cancer (MAPLE): A Randomized, Double-blind, Phase III Study.
    Thatcher N; Goldschmidt JH; Thomas M; Schenker M; Pan Z; Paz-Ares Rodriguez L; Breder V; Ostoros G; Hanes V
    Clin Cancer Res; 2019 Apr; 25(7):2088-2095. PubMed ID: 30617139
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The clinical significance of CXCL16 in the treatment of advanced non-small cell lung cancer.
    Shibata Y; Kobayashi N; Sato T; Nakashima K; Kaneko T
    Thorac Cancer; 2020 May; 11(5):1258-1264. PubMed ID: 32163231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer.
    Herbst RS; O'Neill VJ; Fehrenbacher L; Belani CP; Bonomi PD; Hart L; Melnyk O; Ramies D; Lin M; Sandler A
    J Clin Oncol; 2007 Oct; 25(30):4743-50. PubMed ID: 17909199
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Feasibility study of first-line chemotherapy using Pemetrexed and Bevacizumab for advanced or recurrent nonsquamous non-small cell lung cancer in elderly patients: TORG1015.
    Kozuki T; Nogami N; Kitajima H; Iwasawa S; Sakaida E; Takiguchi Y; Ikeda S; Yoshida M; Kato T; Miyamoto S; Sakamaki K; Shinkai T; Watanabe K
    BMC Cancer; 2016 May; 16():306. PubMed ID: 27177035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FDA's Approval of the First Biosimilar to Bevacizumab.
    Casak SJ; Lemery SJ; Chung J; Fuchs C; Schrieber SJ; Chow ECY; Yuan W; Rodriguez L; Gwise T; Rowzee A; Lim S; Keegan P; McKee AE; Pazdur R
    Clin Cancer Res; 2018 Sep; 24(18):4365-4370. PubMed ID: 29743182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population pharmacokinetic modeling of PF-06439535 (a bevacizumab biosimilar) and reference bevacizumab (Avastin
    Li CSW; Sweeney K; Cronenberger C
    Cancer Chemother Pharmacol; 2020 Mar; 85(3):487-499. PubMed ID: 31768697
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bevacizumab biosimilar BEVZ92 versus reference bevacizumab in combination with FOLFOX or FOLFIRI as first-line treatment for metastatic colorectal cancer: a multicentre, open-label, randomised controlled trial.
    Romera A; Peredpaya S; Shparyk Y; Bondarenko I; Mendonça Bariani G; Abdalla KC; Roca E; Franke F; Melo Cruz F; Ramesh A; Ostwal V; Shah P; Rahuman SA; Paravisini A; Huerga C; Del Campo García A; Millán S
    Lancet Gastroenterol Hepatol; 2018 Dec; 3(12):845-855. PubMed ID: 30262136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with Carboplatin, Paclitaxel, and Bevacizumab for First-Line Nonsquamous Non-Small Cell Lung Cancer.
    von Pawel J; Spigel DR; Ervin T; Losonczy G; Barlesi F; Juhász E; Anderson M; McCall B; Wakshull E; Hegde P; Ye W; Chen D; Chang I; Rhee I; Reck M
    Oncologist; 2018 Jun; 23(6):654-e58. PubMed ID: 29438092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multicenter phase II study on cisplatin, pemetrexed, and bevacizumab followed by maintenance with pemetrexed and bevacizumab for patients with advanced or recurrent nonsquamous non-small cell lung cancer: MAP study.
    Tsutani Y; Miyata Y; Masuda T; Fujitaka K; Doi M; Awaya Y; Kuyama S; Kitaguchi S; Ueda K; Hattori N; Okada M
    BMC Cancer; 2018 Dec; 18(1):1231. PubMed ID: 30526545
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.